Eculizumab as a treatment for atypical hemolytic syndrome secondary to carfilzomib

Nefrologia (Engl Ed). 2019 Jan-Feb;39(1):86-88. doi: 10.1016/j.nefro.2018.02.005. Epub 2018 Apr 30.
[Article in English, Spanish]
No abstract available

Publication types

  • Case Reports
  • Letter
  • Review

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Atypical Hemolytic Uremic Syndrome / chemically induced
  • Atypical Hemolytic Uremic Syndrome / drug therapy*
  • Complement Inactivating Agents / therapeutic use*
  • Female
  • Humans
  • Multiple Myeloma / drug therapy
  • Oligopeptides / adverse effects*

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement Inactivating Agents
  • Oligopeptides
  • carfilzomib
  • eculizumab